PTC Therapeutics Inc

PTCT

Add to Watchlist

71.470USD

-1.250-1.72%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

PTC Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

36 / 155

Overall Ranking

104 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

PTC Therapeutics Inc Highlights

StrengthsRisks

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 84.54% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -28.09, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 104.38M shares, increasing 8.24% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 400.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.42.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

90.000

Target Price

+23.76%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of PTC Therapeutics Inc is 7.14, ranking 120 out of 155 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 272.55M, representing a year-over-year decrease of 76.83%, while its net profit experienced a year-over-year decrease of 100.32%.

Score

Industry at a Glance

Previous score

7.14

Change

0



Financials

5.89

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.91

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.10

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.58

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of PTC Therapeutics Inc is 8.42, ranking 18 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -28.09, which is -132.17% below the recent high of 9.04 and -7.53% above the recent low of -30.20.

Score

Industry at a Glance

Previous score

8.42

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 36/155

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of PTC Therapeutics Inc is 7.33, ranking 103 out of 155 in the Pharmaceuticals industry. The average price target is 80.00, with a high of 118.00 and a low of 55.00.

Score

Industry at a Glance

Previous score

7.33

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of PTC Therapeutics Inc is 7.44, ranking 38 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 79.86 and the support level at 63.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.84

Change

-1.4

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of PTC Therapeutics Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 125.84%, representing a quarter-over-quarter increase of 17.66%. The largest institutional shareholder is Steven Cohen, holding a total of 1.13M shares, representing 1.36% of shares outstanding, with 21.50% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

11.38M

+100.11%

RTW Investments L.P.

7.75M

--

Janus Henderson Investors

4.85M

+28.56%

State Street Investment Management (US)

4.21M

+34.18%

Toronto-Dominion Bank

4.14M

--

TD Securities, Inc.

4.14M

+27.47%

Wellington Management Company, LLP

3.87M

-21.37%

Armistice Capital LLC

2.80M

-14.51%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of PTC Therapeutics Inc is 6.71, ranking 48 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. PTC Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

PTC Therapeutics Inc

PTCT

7.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

9.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment